Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04308564
Recruiting Observational

Laboratory and Clinical Data in Antiphospholipid Patients

NCT04308564 · tracked via the Priya Life Science France tracker
Sponsor
Central Hospital, Nancy, France
Phase
Observational
Started
2021-04-12
Last updated
2021-12-20

Condition(s) studied

Antiphospholipid Syndrome

Investigational drug(s) / intervention(s)

Blood test

Blood test: Blood test for the identification of biomarkers

Study summary

To constitute a registry of antiphospholipid antibodies positive-patients

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * age between 18 and 60 years; * persistent (at least 12 weeks apart) aPL-positivity within 12 months prior to screening Exclusion Criteria: * no inform consent * impossible follow up * pregnancy

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
CHRU de Lille Lille France Not Yet Recruiting
CHRU de Nancy Nancy France Recruiting

More Central Hospital, Nancy, France trials in France

The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients. Recruiting
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial Recruiting
Eating Disorders in Patients With Phenylketonuria Recruiting
Heart Analysis in GATED-PET in Patients Having a Gallium-68-DOTATOC PET/CT Exam for Oncology Indication Recruiting
DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study Starting soon

Other trials for the same condition

Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS) Recruiting
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants Recruiting
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies Recruiting
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome Recruiting
Point of Care Testing INR in Antiphospholipid Syndrome Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04308564 on ClinicalTrials.gov ↗ ← All trials in France